UPDATE: BMO Capital Markets Reiterates Outperform Rating, Raises PT on CareFusion Corporation on FY2Q13 Results

In a report published Friday, BMO Capital Markets reiterated its Outperform rating on CareFusion Corporation CFN, and slightly raised its price target from $34.00 to $35.00. BMO Capital Markets noted, “Expense leverage in the quarter was impressive, with operating margins expanding handsomely to 20.8% from 19.0% y/y and 19.1% q/q, including gross margins that were up 160 bp y/y. This movement is in line with our investment thesis on the stock, which is that while management invests in new products and tuck-in acquisitions (we would have expected more of those by now), it is in a position to drive gross margins and leverage SG&A to expand operating margins, ultimately accelerating top-line growth. Management should be SEC compliant on February 11, 2013, allowing it to reenter the market to repurchase shares.” CareFusion Corporation closed on Thursday at $31.83.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorPrice TargetAnalyst RatingsBMO Capital Markets
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!